Chemical dissociation of human awareness: focus on non-competitive NMDA receptor antagonists.
Journal of Psychopharmacology January 1992 DOI: 10.1177/026988119200600312 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | Phencyclidine, ketamine, and related arylcyclohexylamines produce a dose-dependent dissociation of awareness in humans and are non-competitive NMDA receptor antagonists acting in the receptor ion channel. The author concludes that glutamic acid and related excitatory amino acids are important in maintaining human awareness. |
Abstract
Since the mid-1950s the pharmaceutical industry has developed a number of chemicals, including phencyclidine, ketamine and related arylcyclohexylamines (PCE and TCP), dizocilpine (MK-801), N-allylnormetazocine [ NANM, (±)SKF-10,047], etoxadrol, dioxadrol and its enantiomers dexoxadrol and levoxadrol, which produce a constellation of unusual behavioral effects in animals and man. The compounds best studied in humans are phencyclidine and ketamine. They produce a remarkable dose-dependent dissociation of awareness. All of these substances are now known to be non-competitive antagonists of NMDA receptors of glutamic acid. They act in the NMDA receptor ion channel. One can conclude, on the basis of the effects observed with these agents, that glutamic acid and related excitatory amino acids are extremely important in the maintenance of human awareness.
Citations in the library
Cited by 6
- From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis 2014
- Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics? European Archives of Psychiatry and Clinical Neuroscience February 27, 2024
- Pharmacological characterizations of the 'legal high' fluorolintane and isomers. European Journal of Pharmacology August 15, 2019
- DARK Classics in Chemical Neuroscience: Phencyclidine (PCP). ACS Chemical Neuroscience October 17, 2018
- A methoxydiphenidine-impaired driver International Journal of Legal Medicine March 1, 2016
and 1 more in the library
Cites 4
- Recent advances in the phencyclidine model of schizophrenia American Journal of Psychiatry October 1, 1991
- Study of a New Schizophrenomimetic Drug—Sernyl Archives of Neurology And Psychiatry March 1, 1959
- Stereospecific binding of 3H-phencyclidine in brain membranes. Life Sciences June 21, 1982
- Pharmacologic effects of CI‐581, a new dissociative anesthetic, in man Clinical Pharmacology & Therapeutics May 1, 1965